Lonza Group AG operates as a leading global partner to the life sciences industry, enabling the development and production of innovative therapies. Following its 2026 agreement to divest its Capsules & Health Ingredients business, the company operates as a pure-play CDMO structured around three core segments: Biologics, Small Molecules, and Cell & Gene. The Biologics division is its largest revenue contributor, offering end-to-end clinical and commercial manufacturing services for mammalian and microbial expression systems, bioconjugates, and mRNA. The Small Molecules segment provides integrated drug substance and drug product solutions, while the Cell & Gene division focuses on emerging therapies and personalized medicine. With a geographic footprint encompassing over 30 manufacturing and R&D sites across Europe, North America, and Asia, Lonza supports a diverse client base ranging from emerging biotechs to large global pharmaceutical companies. The company's competitive position is underpinned by its advanced technological platforms, regulatory excellence, and significant capacity for high-complexity manufacturing.
